World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
42013
World Ranking
6532
National Ranking
210

Overview

Piero Ruggenenti is affiliated with the Mario Negri Institute for Pharmacological Research in Italy. Their research primarily focuses on the field of Medicine, with particular emphasis on Nephrology, Infectious Diseases, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Pulmonary and Respiratory Medicine.

Their recent publications include:

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis, 2021, The Lancet
  • Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis, 2021, The Lancet
  • Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial, 2020, The Lancet Diabetes & Endocrinology
  • Glomerular hyperfiltration, 2022, Nature Reviews Nephrology
  • A meta-analysis of GFR slope as a surrogate endpoint for kidney failure, 2023, Nature Medicine

The frequent co-authors who have collaborated extensively with Ruggenenti include Giuseppe Remuzzi, Annalisa Perna, Nadia Rubis, Tobia Peracchi, and Norberto Perico.

The main research topics covered in Ruggenenti's work encompass:

  • Renal Diseases and Glomerulopathies
  • COVID-19 Clinical Research Studies
  • Chronic Kidney Disease and Diabetes
  • Renal Transplantation Outcomes and Treatments
  • Blood Pressure and Hypertension Studies
  • Diabetes Treatment and Management
  • Long-Term Effects of COVID-19

Publications by Ruggenenti appear frequently in venues such as The Nephron journals, Journal of the American Society of Nephrology, The Lancet, Clinical Kidney Journal, and EClinicalMedicine.

Best Publications

  • Preventing microalbuminuria in type 2 diabetes.

    Piero Ruggenenti;Anna Fassi;Anelja Parvanova Ilieva;Simona Bruno

  • Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

    Piero Ruggenenti;Annalisa Perna;Giulia Gherardi;Giovanni Garini

  • Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts

    Brad C. Astor;Kunihiro Matsushita;Ron T. Gansevoort;Marije Van Der Velde

  • Understanding the nature of renal disease progression

    Giuseppe Remuzzi;Piero Ruggenenti;Ariela Benigni

  • Nephropathy in Patients with Type 2 Diabetes

    Giuseppe Remuzzi;Arrigo Schieppati;Piero Ruggenenti

  • Progression, remission, regression of chronic renal diseases.

    Piero Ruggenenti;Arrigo Schieppati;Giuseppe Remuzzi

  • Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial

    Piero Ruggenenti;Annalisa Perna;Giulia Gherardi;Flavio Gaspari

  • Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

    Timothy H.J. Goodship;H. Terence Cook;Fadi Fakhouri;Fernando C. Fervenza

  • Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.

    Piero Ruggenenti;Annalisa Perna;Giacomina Loriga;Maria Ganeva

  • Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

    Piero Ruggenenti;Marina Noris;Giuseppe Remuzzi

  • The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease

    Giuseppe Remuzzi;Norberto Perico;Manuel Macia;Piero Ruggenenti

  • Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

    Piero Ruggenenti;Annalisa Perna;Lidia Mosconi;Roberto Pisoni

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    Kazem Rahimi;Zeinab Bidel;Milad Nazarzadeh;Emma Copland

  • Long-Term Outcome of Renal Transplantation from Older Donors

    Giuseppe Remuzzi;Paolo Cravedi;Annalisa Perna;Borislav D. Dimitrov

  • Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

    Tazeen H Jafar;Paul C Stark;Christopher H Schmid;Marcia Landa

  • Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate.

    Flavio Gaspari;Norberto Perico;Piero Ruggenenti;Lidia Mosconi

  • Early Experience with Dual Kidney Transplantation in Adults using Expanded Donor Criteria

    Giuseppe Remuzzi;Josep Grinyò;Piero Ruggenenti;Marco Beatini

  • Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease

    Aiko P J de Vries;Piero Ruggenenti;Xiong Z Ruan;Xiong Z Ruan;Manuel Praga

  • Rituximab for idiopathic membranous nephropathy

    Giuseppe Remuzzi;Carlos Chiurchiu;Mauro Abbate;Verusca Brusegan

  • ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) CONTROVERSIES CONFERENCE

    Timothy H.J. Goodship;H. Terence Cook;Fadi Fakhouri;Fernando C. Fervenza

Frequent Co-Authors

Giuseppe Remuzzi
Giuseppe Remuzzi Mario Negri Institute for Pharmacological Research
Norberto Perico
Norberto Perico Mario Negri Institute for Pharmacological Research
Andrea Remuzzi
Andrea Remuzzi University of Bergamo
Marina Noris
Marina Noris Mario Negri Institute for Pharmacological Research
Peter Rossing
Peter Rossing University of Copenhagen
Dick de Zeeuw
Dick de Zeeuw University of Groningen
Ariela Benigni
Ariela Benigni Mario Negri Institute for Pharmacological Research
Barry M. Brenner
Barry M. Brenner Brigham and Women's Hospital
Gerjan Navis
Gerjan Navis University Medical Center Groningen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees can be a smart way to begin or advance your medical career in the USA. For those looking for a quicker route to start working in the field, there are 6 month lpn program options that prepare you for entry-level nursing roles in less time.

If you’re seeking advanced practice or specialization, consider the fastest pmhnp program to become a psychiatric mental health nurse practitioner. These accelerated online programs allow you to continue working while developing new skills and expanding your career opportunities.

Another growing avenue is healthcare administration. Earning your MHA online gives you flexible options for learning, with the best online mha programs offering respected curriculums for future leaders. Cost is an important consideration; the cheapest online mha programs can help you manage expenses while pursuing a valuable credential.

These diverse online degrees are tailored for different career goals—whether direct patient care, mental health, or healthcare management—making them excellent pathways alongside or as alternatives to studying traditional Medicine in the USA.

Best Scientists Citing Piero Ruggenenti

Trending Scientists

Recently Published Articles